Retinitis Pigmentosa News and Research

RSS
Retinitis pigmentosa (RP) is the name given to a group of inherited eye diseases that affect the retina (the light-sensitive part of the eye). RP causes the breakdown of photoreceptor cells (cells in the retina that detect light). Photoreceptor cells capture and process light helping us to see. As these cells breakdown and die, patients experience progressive vision loss. The most common feature of all forms of RP is a gradual breakdown of rods (retinal cells that detect dim light) and cones (retinal cells that detect light and color). Most forms of RP first cause the breakdown of rod cells. These forms of RP, sometimes called rod-cone dystrophy, usually begin with night blindness. Night blindness is somewhat like the experience normally sighted individuals encounter when entering a dark movie theatre on a bright, sunny day. However, patients with RP cannot adjust well to dark and dimly lit environments.
UH Eye Institute to use Argus II Retinal Prosthesis System to treat patients with RP

UH Eye Institute to use Argus II Retinal Prosthesis System to treat patients with RP

Effective method to restore sight to patients with blinding diseases

Effective method to restore sight to patients with blinding diseases

EMA grants Sucampo orphan drug designation for unoprostone isopropyl to treat retinitis pigmentosa

EMA grants Sucampo orphan drug designation for unoprostone isopropyl to treat retinitis pigmentosa

Ceregene announces top-line data from CERE-12 Phase 2b clinical study for Parkinson's disease

Ceregene announces top-line data from CERE-12 Phase 2b clinical study for Parkinson's disease

Tacere Therapeutics submits TT-034 clinical trial application to Recombinant DNA Advisory Committee

Tacere Therapeutics submits TT-034 clinical trial application to Recombinant DNA Advisory Committee

Benitec to conduct phase I/II clinical trial of TT-034 in patients with HCV in UCSD site

Benitec to conduct phase I/II clinical trial of TT-034 in patients with HCV in UCSD site

GenSight Biologics announces closing of €32 million Series A financing

GenSight Biologics announces closing of €32 million Series A financing

R-Tech Ueno enrolls retinitis pigmentosa patients in Phase 3 clinical study of UF-021 ophthalmic solution

R-Tech Ueno enrolls retinitis pigmentosa patients in Phase 3 clinical study of UF-021 ophthalmic solution

Wayne State receives U.S. patent allowance for vision restoration technology

Wayne State receives U.S. patent allowance for vision restoration technology

Pediatric blindness etiology varies around the globe

Pediatric blindness etiology varies around the globe

Second Sight Medical Products receives FDA approval for Argus II Retinal Prosthesis System

Second Sight Medical Products receives FDA approval for Argus II Retinal Prosthesis System

Reprogramming eye cells that enable night vision may one day treat retinitis pigmentosa

Reprogramming eye cells that enable night vision may one day treat retinitis pigmentosa

Two recent experimental treatments improve visual function in mouse models of retinitis pigmentosa

Two recent experimental treatments improve visual function in mouse models of retinitis pigmentosa

Carnosic acid promotes eye health

Carnosic acid promotes eye health

Researchers stream braille patterns directly into a blind patient's retina

Researchers stream braille patterns directly into a blind patient's retina

Corneal limbal stromal cells could lead to new treatments for eye conditions

Corneal limbal stromal cells could lead to new treatments for eye conditions

FDA panel recommends U.S. approval for Second Sight’s Argus II bionic eye

FDA panel recommends U.S. approval for Second Sight’s Argus II bionic eye

Experimental stem cell treatment improves vision in blind mice

Experimental stem cell treatment improves vision in blind mice

UC Irvine receives CIRM grant to advance stem cell-based treatments for AD, retinitis pigmentosa

UC Irvine receives CIRM grant to advance stem cell-based treatments for AD, retinitis pigmentosa

Gene therapy approach restores ability to smell in mouse model of congenital anosmia

Gene therapy approach restores ability to smell in mouse model of congenital anosmia

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.